Wrong. A lot of tutes sold because they grew tired of the 3-year declining share price short attack scheme. Naturally, once the price reached a critical point the selling became self-perpetuating, a domino effect. Culminating in an offering at suppresses prices. So the scheme did more than effect the pps, it actually harmed the company. An artificially low share price makes managing a clinical biotech very challenging. Mistakes were made, but nothing to justify this result.
Market Data 
Markets 
AI
